Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Anti-programmed cell death 1 (PD-1) or anti-PD-ligand (L) 1 drugs, as classic immune
checkpoint inhibitors, are considered promising treatment strategies for tumors. In clinical …

PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal
cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab …

Macrophages are a diverse set of cells present in all body compartments. This diversity is
imprinted by their ontogenetic origin (embryonal versus adult bone marrow–derived cells); …

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to
50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate …

In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …

Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and
others have found that a subset of patients experiences paradoxical rapid cancer …

Tumor cells constantly interact with their microenvironment, which comprises a variety of
immune cells together with endothelial cells and fibroblasts. The composition of the tumor …